Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

AACR 2023 | SWOG S1512: pembrolizumab in desmoplastic melanoma

Kari Kendra, MD, PhD, The Ohio State University, Columbus, OH, presents findings from the Phase II SWOG S1512 trial (NCT02775851) of pembrolizumab in patients with desmoplastic melanoma, a form of melanoma commonly found in areas of high sun exposure such as the head and neck. Pembrolizumab was found to produce clinically meaningful, durable responses in the first 9 months of treatment. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.